People who rely on Medicaid continue to get medical care at high rates, and it’s presenting a growing challenge for the major health insurers who cover them.
On Thursday, Elevance Health disclosed in its third quarter earnings release that its medical loss ratio — the amount of premium revenue it spent on medical care — was markedly higher than Wall Street analysts expected, sending its stock price into a tailspin.
Company leaders primarily blamed Medicaid for the underwhelming financial performance. Redeterminations, the process of culling members from Medicaid who are no longer eligible following a pandemic-era pause, are now mostly complete across all states. The members who remain skew sicker and require more health care services. Elevance leaders said they’re working with states to update their payment rates, which tend to be set with a one- to two-year lag.
This article is exclusive to STAT+ subscribers
Unlock this article — and get additional analysis of the financial innards of our health care system — by subscribing to STAT+.
Already have an account? Log in
